Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 125080, 6 pages
Research Article

Anti-Müllerian Hormone as a Sensitive Marker of Ovarian Function in Young Cancer Survivors

1Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Waszyngtona 17, 15-274 Bialystok, Poland
2Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, Poland

Received 15 April 2013; Accepted 7 October 2013

Academic Editor: Kai J. Buhling

Copyright © 2013 Maryna Krawczuk-Rybak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We evaluated ovarian function by measuring the levels of anti-Müllerian hormone (AMH), estradiol, and gonadotropins in 83 young women treated for cancer during childhood and adolescence, and classified according to post-treatment gonadal toxicity versus 38 healthy females. Results. The mean AMH values were lower in the entire cohort independently of the risk group as compared to the control, whereas FSH was elevated only in the high risk group. The lowest AMH values were noted in patients after bone marrow transplantation (BMT) and those treated for Hodgkin lymphoma (HL). Nineteen patients (22.9%) had elevated FSH. They all had low AMH values. Lowered AMH values (but with normal FSH and LH) were observed in 43 patients (51.8%). There was no effect of age at the time of treatment (before puberty, during or after puberty) on AMH levels. Conclusion. Our results show the utility of AMH measurement as a sensitive marker of a reduced ovarian reserve in young cancer survivors. Patients after BMT and patients treated for HL, independently of age at treatment (prepuberty or puberty), are at the highest risk of gonadal damage and early menopause.